Manuel Haas

European Medicines Agency review of ataluren for the treatment of ambulant patients aged 5 years and older with Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene

H. Hillege, S. Bakchine, M. Weise, 2015, Neuromuscular Disorders.

Drug‐induced progressive multifocal leukoencephalopathy in multiple sclerosis: European regulators' perspective

G. Mazzaglia, M. Weise, J. Raine, 2017, Clinical pharmacology and therapeutics.

Development of Exon Skipping Therapies for Duchenne Muscular Dystrophy: A Critical Review and a Perspective on the Outstanding Issues

E. Mercuri, F. Muntoni, B. Sepodes, 2017, Nucleic acid therapeutics.

Regulatory watch: Challenges in drug development for central nervous system disorders: a European Medicines Agency perspective

E. Corruble, F. Butlen-Ducuing, L. Guizzaro, 2016, Nature Reviews Drug Discovery.